Benitec reports Q1 FY2025 net loss $5.1M; positive clinical data for BB-301 in OPMD

Benitec Biopharma Inc.

2025-Q1 EPS reported -$0.48

Net loss $5.1M ($0.48/sh) vs $5.9M ($3.05/sh) prior year; cash $67.8M.
R&D expenses $3.6M, G&A $2.2M; loss from operations $5.8M.
Subject 1 had 35% SSQ Total Score improvement at Day 270; Subject 2 normal swallowing profile at Day 180.
Third subject safely treated with low-dose BB-301 in Oct 2024; fourth expected Dec 2024.
No serious adverse events observed for treated subjects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.